ArticleJournal of ovarian research2026
Development of a surface plasmon resonance sensor for assessing infertility based on Anti-Mullerian hormone levels.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-Müllerian hormone (AMH) is a key biomarker for fertility assessment, but current diagnostic methods lack cost-effectiveness. Plasmonic biosensors can effectively detect low-concentration protein interactions. This study developed a sensitive, label-free surface plasmon resonance (SPR) sensor for AMH detection. Protein G was used to bind anti-AMH antibodies onto a gold chip coated with 11-MUA. Various AMH concentrations were measured to create a standardized graph, establishing limits of detection (LOD) and quantification (LOQ). The biosensor also tested patient serum samples for AMH detection, comparing the results with those obtained from enzyme-linked immunosorbent assay (ELISA) and localized surface plasmon resonance (LSPR) using silica@Au-NRs with anti-AMH antibodies. The detection results indicated a high sensitivity of the nanobiosensors, with LOD and LOQ for the gold chip at 0.6 ng/mL and 1.78 ng/mL, respectively, closely matching those of ELISA and silica@Au-NRs. Additionally, SPR-based biosensors reduce detection costs and measurement time, making them strong candidates for integration into diagnostic kits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.